Introduction

Echinacea purpurea (L.) Moench. (Asteraceae) is commonly used in traditional medicine for the treatment and prevention of upper respiratory tract infections and the common cold. Commercial medicinal preparations of E. purpurea have been shown to possess immunomodulatory and anti-inflammatory effects which explain the traditional use of the plant [1,2]. Furthermore, we have previously shown that lipophilic extracts of
E. purpurea activate PPARy and enhance insulin-stimulated GU in adipocytes in vitro in a dose-dependent manner [3,4] and thus may have an effect on insulin resistance and T2D. Adipose tissue plays a key role in energy homeostasis as a metabolic and endocrine organ. Adipocytes are targets for drugs reducing obesity or ameliorating obesity-associated metabolic disorders such as T2D [5]. TZDs have been used as insulin sensitizers in the management of T2D. TZDs regulate the expression of genes involved in insulin signaling and glucose and lipid metabolism in mature adipocytes but also promote adipocyte differentiation by acting as PPARy full agonists setting into motion gene cascades promoting differentiation and accumulation of triglycerides in adipocytes accentuating adiposity [6]. Furthermore, the potent TZDs cause undesirable side effects, including edema, fluid retention, weight gain, cardiac failure, and hepatotoxicity. Due to the observed hepatotoxicity, two TZD drugs were recently withdrawn from the market and the remaining one, pioglitazone, has been reassessed in light of increased risk of bladder cancer [7]. Limitations of the TZDs have driven research towards new types of drugs, which are able to increase insulin sensitivity acting as PPARy partial agonists, and therefore possibly ameliorate obesity-related insulin resistance without causing the side effects observed in relation to many, if not all, full PPARy agonists. A number of natural plant-derived compounds have been shown to improve insulin sensitivity and may thus serve as starting point for discovery and design of novel drugs and herbal medicine to treat and prevent metabolic disorders with fewer side effects compared to synthetic drugs [8]. The bioactive metabolites considered responsible for the pharmacological activities of E. purpurea comprise polysaccharides, caffeic acid derivatives and alkamides [1,4,9–11]. From the florets of E. purpurea, a C16-alkamide has been isolated that significantly activated PPARy and stimulated GU in adipocytes in vitro [4]. The roots of E. purpurea have a relative high content of alkamides [12–14], of which some are known for their immunomodulatory and anti-inflammatory effects [1,2]. However, very little is known about these bioactive compounds in relation to their effects on GU and PPARy. In the present study, it is shown that a crude DCM extract of E. purpurea roots was able to enhance GU in 3T3-L1 adipocytes and to activate PPARy. Hence, we decided to identify the metabolites responsible for the potential antidiabetic effect of this lipophilic extract using a bioassay-guided fractionation approach. Basal and insulin-dependent GU in adipocytes were used to assess the bioactivity of fractions and isolated compounds. In addition, we determined the PPARy activating properties of active fractions and isolated metabolites in order to determine how their effect on GU in adipocytes correlated with their PPARy activating properties.

Results and Discussion

We have previously screened 133 plant extracts in different assays including PPARy transactivation, adipocyte differentiation, and insulin-dependent GU [3]. In this former investigation, the crude DCM root extract of E. purpurea was found to activate PPARy and to increase insulin-dependent GU, while it did not promote adipogenesis. The present study stays in agreement with these data (Fig. 1, Supporting Information). The results revealed that basal GU in cells treated with the DCM extract was increased approximately 2-fold compared to control and was enhanced in the presence of 3 and 10 nM of insulin, suggesting that the extract increased insulin sensitivity in 3T3-L1 adipocytes (Fig. 1A). Furthermore, the DCM extract was shown to activate PPARy in transfected cell cultures in a dose-dependent manner (Fig. 1B), acting as a weak PPARy agonist compared to the full agonist Rosi, and did not inhibit MDI-induced adipocyte differentiation or promote adipocyte differentiation of DI-treated 3T3-L1 preadipocytes (Fig. 1S). A bioassay-guided approach was used to identify active metabolites from the crude DCM extract with interesting properties in relation to GU. Initial separation of the extract by flash chromatography resulted in nine fractions (A–I), of which fractions A and D were found to increase insulin-dependent GU in the presence of 3 nM and 10 nM insulin (Fig. 1A). The observed effect of the active fractions A and D on GU could be due to the presence of natural products with PPARy activity, and they were therefore tested for this activity. Fractions A and D were found to activate PPARy acting as weak agonists (Fig. 1B). However, the lack of correlation between insulin-dependent GU and PPARy activity (Fig. 1) suggests that the effect on GU uptake, at least partially, may be due to compounds acting as partial agonists. In addition, fractions A and D did not promote adipogenesis using the DI protocol (Fig. 1S, Supporting Information). HPLC-PDA-APCI-MS/MS analysis revealed that fraction A contained fatty acids with a-linolenic acid being a major constituent, while fraction D contained alkamides. a-Linolenic acid is a well-known PPARy agonist [4,15] and has previously been shown to improve glucose tolerance, insulin sensitivity, dyslipidemia, hypertension, and ventricular stiffness in rats [16,17]; thus fraction A was not investigated further. Separation of fraction D by semi-preparative HPLC yielded four alkamides (Fig. 2A), of which

Fig. 1 Effects of dichloromethane extract of Echi

nacea purpurea roots and active fractions A and D on: A Glucose uptake in adipocytes at 100 µg/mL with insulin concentrations of 0, 3, and 10 nM. B PPARy transactivation at 1, 10, and 100 µg/mL. DMSO (vehicle) was set to 1 and the results normalized to this, while Rosi (1 µM) was the positive control. In the PPARy transactivation assay, Rosi was 37-fold relative to DMSO. All values are expressed as mean ± SD of three independent experiments in triplicates; * p < 0.001 indicates significance relative to DMSO. (Color figure available online only.)
two are new isomeric C₁₂-alkamides (1, 2). The known alkamides
dodeca-2E,4E,8Z-trienoic acid isobutylamide (3) and dodeca-
2E,4E-dienoic acid isobutylamide (4) have previously been iso-
lated from the roots of E. purpurea [12, 14, 18].
Compounds 1 and 2 were obtained as an inseparable 1:1 mixture
(compounds 1/2) that gave a quasi-molecular precursor ion at
m/z 262 [M + H]⁺. The molecular formula C₁₇H₂₇NO (5 degrees of
unsaturation) was assigned based on HR-ESI-MS data. The MS/
MS fragmentation pattern of the quasi-molecular precursor ion
of compounds 1/2 showed characteristic product ions for 2-
methylbutylamides (Fig. 3) [13, 14, 19–21]. The presence of a
2-methylbutylamine moiety was confirmed by the ¹H NMR
showing signals at 0.90 (t, J = 7 Hz, H₃-5), 1.17 (m, H-3’b), 1.41 (m, H-2’b), 1.58 (m, H-2’), 3.16 (m, H-1’b), 3.28 (m, H-1’a),
and 5.43 (brs, NH) [12], and was further substantiated by the
¹H–¹H COSY spectrum (Table 1). The UV spectrum
showed absorption maxima at 235 and 261 nm indicating a 2,4-
diene moiety and an additional diene chromophore in the struc-
ture of 1 and 2 [12, 21]. The relative intensities of the fragments at
m/z 149 (100%, base peak) and m/z 147 (24%) of the MS/MS frag-
mentation pattern were in agreement with compounds 1/2 being
2,4-diene alkamides [13, 14, 20]. The presence of four carbon-car-
bon double bonds in 1 and 2 was evident from the ¹H NMR show-
ing signals from 2 × 8 olefinic protons (Table 1). The low-field
shift of the methine proton at C-3 (δ 7.18) confirmed that one of
the double bonds was attached next to the amide moiety [12, 22].
The positions of the other double bonds were determined from
the ¹H–¹H COSY spectrum thus establishing the four double
bonds in positions 2, 4, 8, and 10, respectively (Table 1). The
double bonds in positions 2 and 4 were assigned an E configura-
tion on the basis of a coupling constant of 15 Hz, and the double
bond in position 8 was assigned a Z configuration due to a cou-
pling constant of 11 Hz [12]. Similarly, the double bond in posi-
tion 10 was assigned as being E or Z (Table 1). Hence, the
chemical structure of compounds 1 and 2 was established as dodeca-
2E,4E,8Z,10E/tetraenoic acid 2-methylbutylamide and dodeca-
2E,4E,8Z,10Z/tetraenoic acid 2-methylbutylamide, respectively
(Fig. 2A).
Compounds 3 and 4 showed a weak increase of basal GU and in-
sulin-dependent GU at 3 nM insulin in mature 3T3-L1 cells at
30 µM, whereas no increase of insulin-dependent GU was ob-
served at 10, 30 and 100 nM insulin (Fig. 2S, Supporting Informa-
tion) despite their ability to weakly activate PPARγ, which is, for
compound 4, in accordance with previous investigations [4]. Do-
deca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides are among
the major alkamides in E. purpurea but have previously been
shown not to activate PPARγ [4]. This may also explain why these
alkamides were detected in the non-active fraction F according
to the GU bioassay (data not shown). Compounds 1/2 at 30 µM
significantly increased basal GU 6.3-fold compared to the vehicle
and 3-fold compared to Rosi (Fig. 4A). A significant stimulation
of insulin-dependent GU in the presence of 3, 10, 30 and 100 nM

![Fig. 2](https://example.com/fig2.png)

**Fig. 2** A Chemical structures of alkamides (compounds 1–4) isolated from an active fraction (fraction D) of a dichloromethane root extract of Echina-
coea purpurea. Compounds 1 and 2 were isolated as an inseparable mixture (named compounds 1/2). B Predicted binding modes of compounds 1/2
shown as a 3D representation. C 2D representation of the chemical features of the interaction pattern derived from the docking pose for compound 1.
The interaction pattern is the same for compound 2. Chemical features in the 2D representation are: red arrow = hydrogen-bond donor; blue line = hy-
drophobic contacts. (Color figure available online only.)

![Fig. 3](https://example.com/fig3.png)

**Fig. 3** Proposed fragmenta-
tion pathway of the pro-
tonated molecular
ion (MH⁺) of do-
deca-2E,4E,8Z,10E-
tetraenoic acid 2-methyl-
butylamide (1) as
determined by MS/MS,
including chemical struc-
tures of some of the
most characteristic
fragments. The base
peak fragment at m/z
149 (not shown) is
probably formed when a
double bond of the
original 2,4-diene shifts
to the 3-position, with a
subsequent gain of two
hydrogens [13, 14, 20].
The fragmentation
pathway of the
2E,4E,8Z,10E-isomer (Z)
is the same as illus-
trated above.

![Fig. 4A](https://example.com/fig4a.png)

**Fig. 4A** Supporting Information predicted binding modes of compounds 1/2 shown as a 3D representation. C 2D representation of the chemical features of the interaction pattern derived from the docking pose for compound 1. The interaction pattern is the same for compound 2. Chemical features in the 2D representation are: red arrow = hydrogen-bond donor; blue line = hy-
drophobic contacts. (Color figure available online only.)
insulin was also observed in cells treated with 30 µM of compounds 1/2 (Fig. 4A). Compounds 1/2 also dose-dependently increased GU in the presence of 10 nM insulin (Fig. 4B). The effects of compounds 1/2 on GU resemble those of hexadeca-2E,Z,12Z,14E-tetraenoic acid isobutylamide, previously isolated from the flowers of E. purpurea [4]. Similar to hexadeca-2E,Z,12Z,14E-tetraenoic acid isobutylamide, compounds 1/2 increased transactivation of PPARγ significantly at a concentration of 30 µM compared to vehicle but still weak relative to Rosi (Fig. 5A). Furthermore, compounds 1/2 and Rosi both competed with a fluorescent pan PPAR agonist in a ligand binding assay indicating a common binding site in the PPARγ LBD (Fig. 5B) [23]. These results indicate that compounds 1/2 may function as PPARγ partial agonists. The docking mode and interactions of compounds 1/2 with the LBD (Fig. 2B, C) support the assumption that compounds 1/2 are PPARγ partial agonists. The PPARγ LBD contains a large Y-shaped ligand binding cavity consisting of an entrance (arm III) that branches off into two binding pockets (arm I and II). Arm I is the only substantially polar cavity of the PPARγ LBD, whereas arms II and III are mainly hydrophobic [24,25]. The predicted binding modes of compounds 1/2 with the PPARγ LBD included one hydrogen bond with Ser342 and several hydrophobic contacts with Ala289, Ile281, Ile296, Ile326, Ile341, Leu333, and Met348 from arms II and III of the LBD of PPARγ (Fig. 2C). These contacts are typical for PPARγ partial agonists [24]. The fact that dodeca-2E,4E,Z,8Z,10E/tetraenoic acid isobutylamide do not seem to activate PPARγ suggests that the hydrophobic contacts to Ile341 and Met348 are important for compounds 1/2 being PPARγ partial agonists. In addition, no hydrogen bond interaction between 1/2 and residues Ser289, His323, His449, and/or Tyr473 from arm I of the LBD of PPARγ was predicted, which are typical for PPARγ full agonists. It has been a general notion that the binding mode of PPARγ partial agonists affects the recruitment of co-activators differently from that of full agonists and decreases the transactivation activity of PPARγ resulting in fewer side effects, but still maintains an insulin sensitizing effect [26]. In the present study, the weak activation of PPARγ by compounds 1/2, combined with the results of the competitive PPARγ binding assay and the docking mode of 1/2, suggests that these compounds are acting as PPARγ partial agonists and that the 2-methylbutylamide moiety is important for their activity.

### Table 1

<table>
<thead>
<tr>
<th>H</th>
<th>Compound 1</th>
<th>Compound 2</th>
<th>H–H COSY correlations</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>5.76 d (15 Hz)</td>
<td>5.76 d (15 Hz)</td>
<td>H-3</td>
</tr>
<tr>
<td>3</td>
<td>7.18 dd (15; 11 Hz)</td>
<td>7.18 dd (15; 11 Hz)</td>
<td>H-2, H-4</td>
</tr>
<tr>
<td>4</td>
<td>6.17 dd (15; 11 Hz)</td>
<td>6.17 dd (15; 11 Hz)</td>
<td>H-3, H-5</td>
</tr>
<tr>
<td>5</td>
<td>6.08 dt (15; 7 Hz)</td>
<td>6.08 dt (15; 7 Hz)</td>
<td>H-4, H-6</td>
</tr>
<tr>
<td>6</td>
<td>2.28 m</td>
<td>2.28 m</td>
<td>H-5, H-7</td>
</tr>
<tr>
<td>7</td>
<td>2.28 m</td>
<td>2.28 m</td>
<td>H-6, H-8</td>
</tr>
<tr>
<td>8</td>
<td>5.25 m</td>
<td>5.36 m</td>
<td>H-7, H-9</td>
</tr>
<tr>
<td>9</td>
<td>5.97 dd (11; 11 Hz)</td>
<td>6.30 dd (11; 11 Hz)</td>
<td>H-8, H-10</td>
</tr>
<tr>
<td>10</td>
<td>6.25 dd (15; 11 Hz)</td>
<td>6.32 dd (11; 11 Hz)</td>
<td>H-9, H-11</td>
</tr>
<tr>
<td>11</td>
<td>5.69 dq (15; 7 Hz)</td>
<td>5.55 dq (11; 7 Hz)</td>
<td>H-10, H-12</td>
</tr>
<tr>
<td>12</td>
<td>1.78 brd (7 Hz)</td>
<td>1.75 brd (7 Hz)</td>
<td>H-11</td>
</tr>
</tbody>
</table>

### Fig. 4

Effect of compounds 1/2 on insulin-dependent glucose uptake: A: At 30 µM of compounds 1/2 with insulin concentrations of 0, 3, 10, 30 and 100 nM. B: Dose-dependent effect of compounds 1/2 at 10 nM insulin. DMSO (vehicle) was set to 1 and the results normalized to this, while Rosi (1 µM) was the positive control. All values are expressed as mean ± SD of three independent experiments in triplicates; *p < 0.001 indicates significance relative to DMSO. (Color figure available online only.)

---

Kotowska D et al. Isomeric C₁₂-Alkamides from... Planta Med 2014; 80: 1712–1720
The alkamides are structurally related to natural endogenous and/or dietary PPAR ligands such as fatty acids [27, 28], prostanooids [28, 29], phospholipids [30], and polyacetylenes [31]. The PPARy activating properties of these ligands depend on the length of their aliphatic chain and functional groups such as carboxyl/carboxyl, α,β-unsaturated ketone, and/or hydroxyl, and thus on their interactions with the LBD. For example, the PPARy activating properties of some endogenous prostanooids and oxidized polyunsaturated fatty acids seem to be related to their ability to bind covalently to Cys285 of PPARy LBD through a Michael addition reaction with an α,β-unsaturated ketone [32–34]. Polyacetylenes of the falcarindiol-type containing hydroxyl groups at one or two positions along their C17-aliphatic chain were also shown to display PPARy partial agonism, which was confirmed by molecular docking studies suggesting a binding to the LBD in a manner similar to that observed for compounds 1/2 and other PPARy partial agonists [31]. However, the large cavity of the PPARy LBD, and thus the broad specificity of this receptor, makes the prediction of PPARy activity of ligands such as alkamides and other fatty acid derivatives difficult based on their chemical structure alone, in accordance with the results of the present study.

Increased expression of adipose cell differentiation markers is associated with insulin sensitivity [35], which may to some extent explain the insulin-dependent and basal GU data obtained in this study. The critical window for ligand-dependent induction of adipocyte differentiation of 3T3-L1 preadipocytes is days 0 to 4 after induction of differentiation [36]. To investigate possible mechanisms by which compounds 1/2 might affect the early stages of adipocyte differentiation, we examined the expression of genes involved in adipogenesis (PPARγ, C/EBPα, and αP2, also known as fatty acid binding protein 4), glucose transport (Glut1 and Glut4), lipogenesis (SCD1), and adipokine (adiponectin) (Table 2) in mature 3T3-L1 cells treated with 30 µM of compounds 1/2 during the first 4 days of differentiation (days 0–4) using the DI and MDI protocols. Compounds 1/2 increased the expression of PPARγ, αP2, C/EBPα, adiponectin and Glut1 in the MDI differentiation medium (Fig. 6A). However, when the CAMP elevating agent 1-methyl-3-isobutylxanthine was omitted in the cocktail (DI differentiation medium), the expression of several genes was significantly downregulated (Fig. 6B). These results suggest that compounds 1/2 require elevated CAMP levels to increase the expression of key markers of adipogenesis. SCD1 expression was significantly downregulated by treatment with 30 µM of compounds 1/2 in both the MDI and DI treatment (Fig. 6C). SCD1 is involved in lipogenesis, and therefore a downregulation of this gene may result in decreased lipogenesis and a small size of lipid droplets [37].

PPARy agonists are known to increase glucose transport and insulin sensitivity by regulating expression of several genes involved in glucose metabolism [38]. GU in adipocytes is correlated with the number of glucose transporters [39]. Glut1 is expressed in both preadipocytes and mature adipocytes and is responsible for basal glucose transport. By contrast, Glut4 is expressed only in mature adipocytes and supports insulin-dependent GU [40, 41]. In this study, compounds 1/2 increased gene expression of Glut1,
but not Glut4, when the MDI differentiation medium was used (Fig. 6A), whereas compounds 1/2 decreased the expression of the Glut4 transporter and did not significantly affect the expression of the Glut1 transporter in the DI differentiation medium (Fig. 6B). This could indicate that compounds 1/2 in the context of MDI-induced differentiation enhanced basal GU by upregulation of Glut1 gene expression, whereas the observed insulin-dependent GU requiring Glut4 was unrelated to an increased expression of this transporter.

Adiponectin also plays an important role in mediating GU in adipocytes and was significantly upregulated by addition of compounds 1/2 in the MDI protocol (Fig. 6A), whereas the observed insulin-dependent GU requiring Glut4 was unrelated to an increased expression of this transporter.

Plant extraction and isolation

Fresh E. purpurea roots (3 kg) were homogenized and extracted twice with DCM (10 L) for 24 h in the dark at 5°C with periodical shaking. The extracts were combined, filtered, and dried under vacuum (30°C) to give 9.3 g crude DCM extract (yield (w/w): 0.31%).

Initial separation of the DCM extract was done on a flash column (100 mm i.d., 300 g silica gel) conditioned with 100% MeCN. 70 fractions (600 mL each), and 100% MeCN (1000 mL). Seventy fractions (100 mL each) were collected and combined into nine fractions (A–I) based on TLC: A (1.6 g), B (0.3 g), C (0.1 g), D (0.2 g), E (0.1 g), F (0.4 g), G (0.2 g), H (0.5 g), and I (2.9 g). TLC plates were developed using n-hexane-EtOAc (60:40) as eluent and were inspected by UV light followed by visualization with vanillin reagent. Testing of the fractions A–I in the GU bioassay revealed two active fractions, A and D (Fig. 1A), which were further tested in the PPARα transactivation bioassay (Fig. 1B). Non-active fractions according to the GU bioassay (fraction B, C, E–I, data not shown) were not tested for PPARα activity.

The active fractions A and D were analyzed by HPLC-PDA-APCI-MS/MS according to the method described by Thomsen et al. [14]. Fraction A was found to contain fatty acids with α-linolenic acid as a major constituent. Fraction D contained alkamides and was re-dissolved at a concentration of 10 mg/mL in MeCN and separated by semi-preparative HPLC. Mobile phase: (A) water

Materials and Methods

Plant material

Plants of Echinacea purpurea (L.) Moench were propagated from seeds purchased from Rieger Hoffmann GmbH. The plantlets were raised in a greenhouse and transplanted in a sandy loam soil (Aarslev, Denmark; coordinates: 55.3° N, 10.5° E) in early June 2007. The roots were harvested in August 2010, washed and air-dried and stored at −25°C until use. E. purpurea plants were authenticated by one of the authors (Dr. Kai Grevsen), and a voucher specimen (EP2010) is deposited at the Department of Food Science, Aarhus University, Denmark.

Apparatus, materials, chemicals, and reagents

Semi-preparative HPLC was performed on a Dionex UltiMate 3000 binary semipreparative LC system (Thermo Scientific), equipped with a DAD (DAD-3000 RS) and a Foxy Jr. fraction collector (Teledyne ISCO Inc.). Separations were performed on a Develosil ODS-HG-5 RP-C18 column (5 μm; 250 × 20 mm i.d., Nomura Chemical Co.). UV and MS data were collected from an UPLC-PDA-MS/MS system, LTQ XL (Linear Quadrupole 2D Ion Trap, Thermo Scientific) mass spectrometer attached to a PDA detector. HR-ESI-MS was recorded on a 10205 micrOTOF-Q II focus high resolution mass spectrometer (Bruker Daltonics). NMR spectra were recorded on a Bruker 400 MHz spectrometer. Flash chromatography was performed in silica gel 60, particle size 0.063–0.2 mm, Merck and TLC in silica gel 60 aluminium sheets; 0.2 mm, 20 × 20 cm, Merck. MeCN, EtOAc, DCM, n-hexane, isopropanol, TFA, DMSO, dexamethasone, 1-methyl-3-isobutylxanthine, insulin, Oil Red O, and Rosi (HPLC purity ≥98%) were purchased from Sigma-Aldrich: DMEM, FCS, CS, PBS, penicillin/streptomycin, and TRLzol reagent from Invitrogen.
containing 500 ppm TFA and (B) 100% MeCN containing 500 ppm TFA. Solvent gradient: 0 min, 25% B; 55 min, 100% B; 70 min, 100% B; 85 min, 25% B; column temperature 25°C; flow rate was 5 mL/min; injection volume was 2 mL; detection wavelengths were λ = 210, 254, and 280 nm. Separation of fraction D resulted in the isolation of dodeca-2,4E,8Z,10E-tetraenoic acid 2-methylbutyramide (1) and dodeca-2,4E,8Z,10Z-tetraenoic acid 2-methylbutyramide (2) as an 1:1 inseparable mixture (5.9 mg, HPLC purity ≥96%; tR = 36.9 min) named compounds 1/2, and the known metabolites dodeca-2,4E,8Z-trienoic acid iso- butyramide (3; 22.3 mg, HPLC purity ≥96%; tR = 38.4 min) and dodeca-2,4E-dienoic acid isobutyramide (4; 17.5 mg, HPLC purity ≥98%; tR = 44.7 min). Compounds 1/2 were obtained as colourless oil; UV λmax (nm): 235, 261. 1H NMR (CDCl3, 400 MHz), see Table 1 and Supporting Information. HPLC-MS/MS (APCI; positive mode): m/z 262 [M + H]+ (quasi-molecular precursor ion) gave the following product ions (intensities in % relative to base peak in parenthesis): m/z 234 (4) [M + H – C2H4]+; 206 (3) [M + H – C3H5]+; 192 (6) [M + H – C3H5]+; 175 (28) [M + H – C2H3N]+; 149 (100), 147 (24) [M + H – C2H3NO]+, 133 (13), 121 (13) [M + H – C2H3NO]+; 107 (18), 93 (15), 91 (6) [see also Supporting Information]. HR ESI-MS m/z 262.2176 [M(C17H27NO) + H]+ (calcd. 262.2171) [Supporting Information]. The structures of compounds 3 and 4 were established based on comparison of NMR and MS data with literature reports [12,14,18].

Adipocyte cell cultures

3T3-L1 preadipocytes were cultured in DMEM with 10% CS supplemented with 1% penicillin/streptomycin at 37°C in humidified 95% air and 5% CO2. At day two post-confluence (designated day 0), the cells were induced to differentiate with 500 µM 1-methyl-3-isobutylxanthine, 1 µM dexamethasone, and 167 nM insulin (MDI protocol), or with 1 µM dexamethasone and 167 nM insulin (DI protocol). For both protocols, the medium was replaced at day 2 with DMEM supplemented with 10% FCS, 1% penicillin/streptomycin, and 167 nM insulin and thereafter every second day with DMEM supplemented with 10% FCS and 1% penicillin/streptomycin. Extract, fractions, and pure compounds were dissolved in 0.1% (v/v) DMSO and thereafter added to the medium to a final concentration as indicated. Vehicle cells were treated with 0.1% (v/v) DMSO equal to the DMSO concentration in the medium. Mature adipocytes were treated with the compounds until day 8. At day 10, cells were washed in PBS, fixed with 4% paraformaldehyde for 1 h and washed with double-distilled water. Cells were incubated with Oil Red O solution (8.57 mM Oil Red O in isopropanol) mixed 3:2 with water for 30 min and washed twice in water.

Glucose uptake in adipocytes

Mature 3T3-L1 cells were seeded in 96-well plates and differentiated according to DI or MDI protocol and treated every second day with the designated medium and DMSO, Rosi (1 µM), crude extract, fractions, or pure compounds until day 8. At day 10, cells were washed in PBS, fixed with 4% paraformaldehyde for 1 h and washed with double-distilled water. Cells were incubated with Oil Red O solution (8.57 mM Oil Red O in isopropanol) mixed 3:2 with water for 30 min and washed twice in water.

Glucose uptake in adipocytes

Mature 3T3-L1 cells were seeded in 96-well plates and differentiated according to the MDI protocol till day 8. Mature 3T3-L1 adipocytes were fed with medium supplemented with DMSO, Rosi (1 µM), and crude extract, fractions, or pure compounds. Glucose uptake in adipocytes was determined by a fluorometric method using 2-N-(2-naphthyl)ethyl-3-[(p-nitrophenyl)azo]-5-[(p-nitrophenyl)azosulfanilic acid (NAP-Anthranilic Acid, Sigma-Aldrich). Cells were treated with 0.1% (v/v) DMSO as a control. The active site was determined by selecting all residues of the ligand (e.g., PPARγ PBD) and calculating the interaction energy (ΔE) as a measure for binding affinities.

Molecular docking studies

Docking studies were performed using GOLD version 5.1 [43] and default parameters (GoldScore, 100% search efficiency). Protein Data Bank entry 2Q5S (human PPARγ) was selected as protein template. The active site was determined by selecting all residues within a radius of 6 Å of the co-crystallized ligand for 2Q5S. Docking was performed with a hydrogen bond to Ser342 set to constraint since this interaction has been reported to be essential for binding of PPARγ partial agonists [23]. After docking, all compounds were minimized using LigandScout’s general purpose MMFF94 implementation [44]. The best docking poses for the ligands were selected by developing a 3D pharmacophore with LigandScout [45–47].

Real-time quantitative polymerase chain reaction

Total RNA was isolated on day 10 from maturing (days 0–4) 3T3-L1 adipocytes using TRIzol reagent. 500 ng of RNA were reverse transcribed with RevertAid (Fermentas) according to manufacturer’s instructions. qPCR analysis was performed using the Mx3000P qPCR system (Agilent Technologies) and SYBRGreen JumpStart Taq ReadyMix (Sigma-Aldrich). Primers were purchased from Tag Copenhagen A/S. Data was analyzed using the ΔΔCt method, and gene expression was normalized to TATA box template. The active site was determined by selecting all residues of the ligand (e.g., PPARγ PBD) and calculating the interaction energy (ΔE) as a measure for binding affinities.

Statistical analysis

All data were analyzed by SAS statistical programming software (version 9.2; SAS Institute Inc.) and OriginPro software (OriginPro 8.0, OriginLab Corporation). Data were expressed as the mean ± standard deviation (SD) of three independent experiments in triplicates. The identification of significances between different groups was carried out with Student’s t-test. A p value < 0.05 was considered statistically significant.
Supporting information

Adipocyte differentiation of DI protocol-treated 3T3-L1 preadi-
pocytes with DMSO, 100 µg/mL DCM extract, fraction A, fraction D, 30 µM compounds 1/2, and 1 µM Rosi, respectively (Fig. 15), the effect of compounds 3 and 4 at a 30 µM concentration on in-
sulin-dependent GU (Fig. 25), and the HR-ESI-MS, MS/MS, H NMR and ‘H–’H COSY spectra of compounds 1/2 are available as Supporting Information.

Acknowledgements

This research was supported by the Danish Council for Strategic Research (Project No. 09–063086).

Conflict of Interest

The authors declare no conflict of interest.

Affiliations

1 Department of Biology, University of Copenhagen, Copenhagen, Denmark
2 Department of Chemical Engineering, Biotechnology and Environmental Technology, University of Southern Denmark, Odense, Denmark
3 Computer-Aided Drug Design, Institute of Pharmacy, Medicinal and Pharma-
ceutical Chemistry, Free Universitat Berlin, Berlin, Germany
4 Department of Food Science, Aarhus University, Aarslev, Denmark
5 Department of Food Science, Aarhus University, Aarslev, Denmark

References

4 Christensen KB, Petersen RK, Petersen S, Kristiansen K, Christensen LP. Activation of PPARy by metabolites from the flowers of purple cone-
8 Yeh GY, Eisenberg DM, Kaptchnik TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabe-
tes Care 2013; 36: 1277–1294
9 Starvaggi Cucuzza L, Motta M, Accornero P, Baratta M. Effect of Echinacea angustifolia extract on cell viability and differentiation in mam-
10 Spelman K, Liams-Hauser K, Cech NB, Taylor EW, Smirnoff N, Wenner CA. Activation of PPARγ in IL-2 inhibition in T cells by Echinacea-derived undeca-
2E-ene-8,10-dioic acid isobutyramide. Int Immunopharmacol 2009; 9: 1200–1206
11 Goey AKL, Rosing H, Meijerman I, Spiranidis RW, Schellins JHM, Beijnen JH. The bioanalysis of the major Echinacea purpurea constituents do-
deca-2E,4E,8Z,10E/Z-tetraenoic acid isobutyramides in human plasma using LC-MS/MS. J Chromatogr B 2012; 902: 151–156
14 Thomsen MO, Frett XC, Christensen KB, Christensen LP, Greven K. Sea-
sonal variations in the concentrations of lipophilic compounds and phenolic acids in the roots of Echinacea purpurea and Echinacea pal-
15 Takahara Y, Kobayashi T, Takemoto K, Adachi T, Osaki K, Kawahara K. Tsujimoto G. Pharmacogenomics of cardiovascular pharmacology: de-
velopment of an informatics system for analysis of DNA microarray da-
ta with a focus on lipid metabolism. J Pharmcol Sci 2008; 107: 1–7
20 Mudge E, Loes-Lutz D, Brown P, Scheiber A. Analysis of alkylamides in Echinacea purpurea materials and dietary supplements by ultrafast li-
quid chromatography with diode array and mass spectrometric detec-
21 Pellati F, Epifano F, Contaldo N, Orlandini G, Cavicchi L, Genovesi S, Ben-
23 Atanasov AG, Mosley R, Surwit RS, Moller DE. Peroxisome proliferator-activated re-
ceptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 2007; 1771: 915–925
27 Dussault I, Forman BM. Prostaglandins and fatty acids regulate tran-
scriptional signaling via the peroxisome proliferator activated receptor nuclear receptors. Prostaglandins Other Lipid Mediat 2000; 62: 1–13
phospholipids are generated by monocytes and macrophages, de-
tive partial agonists of peroxisome proliferator-activated receptor-
gamma. Planta 2013; 283: 16755
30 Waku T, Shiraki T, Oyama T, Fujimoto Y, Moebara K, Kamiya N, Jingami H, Morikawa K. Structural insight into PPARγ activation through con-


